Skip to main content
Evidence Snapshot

Translocator protein

CHEMBL4552 SINGLE PROTEIN Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4552
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Translocator protein as ChEMBL target CHEMBL4552, mapped to UniProt P16257. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Translocator protein
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL4552
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P16257
Translocator protein
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Translocator protein matters

As of 2026-09-13

Translocator protein is reviewed as Translocator protein (UniProt P16257); the current evidence base includes 10 approved drugs, 1131 compounds, and 235 assays, with lead potency reaching pChEMBL 10.4.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 1131 compounds, and 235 assays for this target. The dominant activity type is KI. CHEMBL63064 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL63064 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Translocator protein matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P16257, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1131
Total Compounds
235
Total Assays
10
Approved Drugs
IC50: 699.0, KI: 959.0, KD: 14.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL63064
 10.4 Ki —
No preferred name
CHEMBL2070800
 10.3 Ki —
No preferred name
CHEMBL2070787
 10.3 Ki —
No preferred name
CHEMBL5288131
 10.2 Ki —
No preferred name
CHEMBL401000
 10.1 Ki —

Approved Drugs

Structure Compound First Approval
MIDAZOLAM
CHEMBL655
 1985
VERAPAMIL
CHEMBL6966
 1981
NIFEDIPINE
CHEMBL193
 1981
DIAZEPAM
CHEMBL12
 1963
CHLORDIAZEPOXIDE
CHEMBL451
 1960
ALPIDEM
CHEMBL54349
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4552